keyword
MENU ▼
Read by QxMD icon Read
search

Y90

keyword
https://www.readbyqxmd.com/read/27878478/liver-resection-after-selective-internal-radiation-therapy-with-yttrium-90-is-safe-and-feasible-a-bi-institutional-analysis
#1
G Paul Wright, J Wallis Marsh, Manish K Varma, Michael G Doherty, David L Bartlett, Mathew H Chung
BACKGROUND: Treatment with yttrium-90 (Y90) microspheres has emerged as a viable liver-directed therapy for patients with unresectable tumors and those outside transplantation criteria. A select number of patients demonstrate a favorable response and become candidates for surgical resection. METHODS: Patients who underwent selective internal radiation therapy (SIRT) with Y90 microspheres at two institutions were reviewed. Patients who underwent liver resection were included in the study...
November 22, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27601017/a-lesion-based-response-prediction-model-using-pretherapy-pet-ct-image-features-for-y90-radioembolization-to-hepatic-malignancies
#2
Rahul Mehta, Kejia Cai, Nishant Kumar, M Grace Knuttinen, Thomas M Anderson, Hui Lu, Yang Lu
We present a probabilistic approach to identify patients with primary and secondary hepatic malignancies as responders or nonresponders to yttrium-90 radioembolization therapy. Recent advances in computer-aided detection have decreased false-negative and false-positive rates of perceived abnormalities; however, there is limited research in using similar concepts to predict treatment response. Our approach is driven by the goal of precision medicine to determine pretherapy fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography imaging parameters to facilitate the identification of patients who would benefit most from yttrium-90 radioembolization therapy, while avoiding complex and costly procedures for those who would not...
September 6, 2016: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/27600383/connecting-cancer-biology-and-clinical-outcomes-to-imaging-in-kras-mutant-and-wild-type-colorectal-cancer-liver-tumors-following-selective-internal-radiation-therapy-with-yttrium-90
#3
Michael J Magnetta, Anish Ghodadra, Steven J Lahti, Minzhi Xing, Di Zhang, Hyun S Kim
PURPOSE: To determine whether pathologic colorectal tumor KRAS mutation status is correlated with progression-free survival (PFS) by imaging after selective internal radiation therapy with Yttrium-90 (SIRT Y90) for metastatic colorectal cancer in the liver (mCRC). MATERIALS AND METHODS: This was an IRB approved, HIPAA compliant retrospective cohort study. Consecutive patients with unresectable mCRC with documented KRAS mutation status treated at a single center from 2002 to 2013 with SIRT Y90 were investigated...
September 6, 2016: Abdominal Radiology
https://www.readbyqxmd.com/read/27575820/y90-radioembolization-significantly-prolongs-time-to-progression-compared-with-chemoembolization-in-patients-with%C3%A2-hepatocellular-carcinoma
#4
Riad Salem, Andrew C Gordon, Samdeep Mouli, Ryan Hickey, Joseph Kallini, Ahmed Gabr, Mary F Mulcahy, Talia Baker, Michael Abecassis, Frank H Miller, Vahid Yaghmai, Kent Sato, Kush Desai, Bartley Thornburg, Al B Benson, Alfred Rademaker, Daniel Ganger, Laura Kulik, Robert J Lewandowski
BACKGROUND & AIMS: Conventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a tumor. We performed a randomized, phase 2 study to compare the effects of cTACE and Y90 radioembolization in patients with HCC. METHODS: From October 2009 through October 2015, we reviewed patients with HCC of all Barcelona Clinic Liver Cancer (BCLC) stages for eligibility...
December 2016: Gastroenterology
https://www.readbyqxmd.com/read/27574586/yttrium-90-resin-microspheres-as-an-adjunct-to-sorafenib-in-patients-with-unresectable-hepatocellular-carcinoma
#5
Armeen Mahvash, Ravi Murthy, Bruno C Odisio, Kanwal Pratap Raghav, Lauren Girard, Sheree Cheung, Van Nguyen, Joe Ensor, Sameer Gadani, Khaled M Elsayes, Reham Abdel-Wahab, Manal Hassan, Ahmed S Shalaby, James C Yao, Michael J Wallace, Ahmed O Kaseb
PURPOSE: The safety and efficacy of the combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) to treat advanced hepatocellular carcinoma (HCC) is not well established. We determined the incidence of adverse events with this combination therapy in patients with advanced HCC at our institution and analyzed the treatment and survival outcomes. MATERIALS AND METHODS: We reviewed the records of 19 patients with Barcelona Clinic Liver Cancer class B or C HCC who underwent treatment with Y90 RMS (for 21 sessions) while receiving full or reduced doses of sorafenib between January 2008 and May 2010...
2016: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/27495316/yttrium-90-radioembolization-for-hepatocellular-carcinoma-prior-to-liver-transplantation
#6
Giuseppe Maria Ettorre, Giovanni Battista Levi Sandri, Andrea Laurenzi, Marco Colasanti, Roberto Luca Meniconi, Raffaella Lionetti, Roberto Santoro, Pasquale Lepiane, Rosa Sciuto, Giuseppe Pizzi, Roberto Cianni, Rita Golfieri, Gianpiero D'Offizi, Adriano M Pellicelli, Mario Antonini, Giovanni Vennarecci
BACKGROUND: Liver transplantation (LT) is a well-established procedure for hepatocellular carcinoma (HCC) within the Milan criteria. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. We retrospectively evaluate the efficacy of the Y90-RE in patients with HCC prior to LT. METHODS: From January 2002 to December 2015, 365 patients were transplanted at the San Camillo Hospital Center. One hundred forty-three patients were transplanted for HCC, and in 22 cases the patients were treated with Y90-RE before LT...
August 5, 2016: World Journal of Surgery
https://www.readbyqxmd.com/read/27439702/y90-radioembolization-in-chemo-refractory-metastastic-liver-dominant-colorectal-cancer-patients-outcome-assessment-applying-a-predictive-scoring-system
#7
Robert Damm, Ricarda Seidensticker, Gerhard Ulrich, Leonie Breier, Ingo G Steffen, Max Seidensticker, Benjamin Garlipp, Konrad Mohnike, Maciej Pech, Holger Amthauer, Jens Ricke
BACKGROUND: In treatment-refractory liver dominant metastatic colorectal cancer, the role of liver directed therapies still is unclear. We sought to determine a prognostic score for Y90 radioembolization in these patients. METHODS: We analyzed 106 patients with refractory liver dominant mCRC who had undergone a total of 178 Y90 radioembolizations with resin microspheres was collected. Potential factors influencing survival were analyzed using a Cox regression. The Log rank test served to establish prognostic factors and to form a clinical score for outcome prediction after Y90 radioembolization...
July 20, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27390539/yttrium-90-selective-internal-radiation-therapy-with-glass-microspheres-for-hepatocellular-carcinoma-current-and-updated-literature-review
#8
REVIEW
Edward Wolfgang Lee, Lourdes Alanis, Sung-Ki Cho, Sammy Saab
Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor...
July 2016: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
https://www.readbyqxmd.com/read/27039186/transarterial-radioembolization-with-yttrium-90-for-the-treatment-of-hepatocellular-carcinoma
#9
REVIEW
Joseph Ralph Kallini, Ahmed Gabr, Riad Salem, Robert J Lewandowski
BACKGROUND: Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC. METHODS: The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC...
May 2016: Advances in Therapy
https://www.readbyqxmd.com/read/26971850/liver-transplantation-for-the-treatment-of-neuroendocrine-liver-metastases
#10
REVIEW
Valery Vilchez, Roberto Gedaly
Neuroendocrine neoplasms represent a heterogeneous group of cancers arising from a variety of neuroendocrine cell types. In general, these tumors (NET) are asymptomatic and are discovered late once metastatic disease is present (40-80%). The liver is the most common organ involved when metastases occur (40-93%), followed by bone (12-20%) and lungs (8-10%). A number of different therapeutic options are available for patients with hepatic metastases including surgical resection, transplantation, transarterial chemoembolization, radiofrequency and microwave ablation, radioembolization (Y90), chemotherapy, somatostatin analogues and molecular targeted therapies...
January 2016: Best Practice & Research. Clinical Endocrinology & Metabolism
https://www.readbyqxmd.com/read/26964779/lung-shunt-fraction-prior-to-yttrium-90-radioembolization-predicts-survival-in-patients-with-neuroendocrine-liver-metastases-single-center-prospective-analysis
#11
Johannes M Ludwig, Emily McIntosh Ambinder, Anish Ghodadra, Minzhi Xing, Hasmukh J Prajapati, Hyun S Kim
OBJECTIVE: To investigate survival outcomes following radioembolization with Yttrium-90 (Y90) for neuroendocrine tumor liver metastases (NETLMs). This study was designed to assess the efficacy of Y90 radioembolization and to evaluate lung shunt fraction (LSF) as a predictor for survival. METHODS: A single-center, prospective study of 44 consecutive patients (median age: 58.5 years, 29.5 % male) diagnosed with pancreatic (52.3 %) or carcinoid (47.7 %) NETLMs from 2006 to 2012 who underwent Y90 radioembolization was performed...
July 2016: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/26847353/hepatectomy-after-yttrium-90-y90-radioembolization-induced-liver-fibrosis
#12
Ajay V Maker, Carey August, Vijay K Maker, Elliot Weisenberg
An obese 55-year-old woman with nonalcoholic fatty liver disease presented 7 years after resection of a T3N1 ileal carcinoid tumor with an elevated chromogranin A, multifocal metastatic disease to the liver, and carcinoid syndrome. She underwent right hepatic artery yttrium-90 (Y90) radioembolization, followed a month later by selective Y90 treatment to segment IV. She then presented to our clinic 10 months later, remaining symptomatic with flushing, diarrhea, anxiety, myalgia, pain, and persistent night sweats despite Sandostatin administration...
April 2016: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/26776845/a-systematic-review-of-contralateral-liver-lobe-hypertrophy-after-unilobar-selective-internal-radiation-therapy-with-y90
#13
REVIEW
Jin-Yao Teo, John C Allen, David C Ng, Su-Pin Choo, David W M Tai, Jason P E Chang, Foong-Khoon Cheah, Pierce K H Chow, Brian K P Goh
BACKGROUND: Curative liver resection is the treatment of choice for both primary and secondary liver malignancies. However, an inadequate future liver remnant (FLR) frequently precludes successful surgery. Portal vein embolization is the gold-standard modality for inducing hypertrophy of the FLR. In recent times, unilobar Yttrium-90 selective internal radiation therapy (SIRT) has been reported to induce hypertrophy of the contralateral, untreated liver lobe. The aim of this study is to review the current literature reporting on contralateral liver hypertrophy induced by unilobar SIRT...
January 2016: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/26635340/90y-radioembolization-of-colorectal-hepatic-metastases-using-glass-microspheres-safety-and-survival-outcomes-from-a-531-patient-multicenter-study
#14
Ryan Hickey, Robert J Lewandowski, Totianna Prudhomme, Eduardo Ehrenwald, Brian Baigorri, Jeffrey Critchfield, Joseph Kallini, Ahmed Gabr, Boris Gorodetski, Jean-Francois Geschwind, Andrea Abbott, Ravi Shridhar, Sarah B White, William S Rilling, Brendan Boyer, Shannon Kauffman, Sharon Kwan, Siddarth A Padia, Vanessa L Gates, Mary Mulcahy, Sheetal Kircher, Halla Nimeiri, Al B Benson, Riad Salem
UNLABELLED: Hepatic metastases of colorectal carcinoma are a leading cause of cancer-related mortality. Most colorectal liver metastases become refractory to chemotherapy and biologic agents, at which point the median overall survival declines to 4-5 mo. Radioembolization with (90)Y has been used in the salvage setting with favorable outcomes. This study reports the survival and safety outcomes of 531 patients treated with glass-based (90)Y microspheres at 8 institutions, making it the largest (90)Y study for patients with colorectal liver metastases...
May 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/26559021/transarterial-y90-radioembolization-versus-chemoembolization-for-patients-with-hepatocellular-carcinoma-a-meta-analysis
#15
COMPARATIVE STUDY
Yafei Zhang, Yiming Li, Hong Ji, Xin Zhao, Hongwei Lu
Transarterial chemoembolization (TACE) is one of the standard locoregional treatments for intermediate stage hepatocellular carcinoma (HCC). Transarterial radioembolization (TARE) using β-emitting yttrium-90 (90Y) integral to the glass matrix of the microspheres has been developed as an alternative to TACE in recent years. Thus, we conducted a meta analysis to evaluate the safety and efficacy of TARE versus TACE for unresectable HCC. We searched PubMed, EMBASE, Web of science and the Cochrane Library for clinical trials comparing TARE with TACE for unresectable HCC...
October 2015: Bioscience Trends
https://www.readbyqxmd.com/read/26472490/a-systematic-review-of-contralateral-liver-lobe-hypertrophy-after-unilobar-selective-internal-radiation-therapy-with-y90
#16
Jin-Yao Teo, John C Allen, David C Ng, Su-Pin Choo, David W M Tai, Jason P E Chang, Foong-Khoon Cheah, Pierce K H Chow, Brian K P Goh
BACKGROUND: A curative liver resection is the treatment of choice for both primary and secondary liver malignancies. However, an inadequate future liver remnant (FLR) frequently precludes successful surgery. Portal vein embolization is the gold-standard modality for inducing hypertrophy of the FLR. In recent times, unilobar Yttrium-90 selective internal radiation therapy (SIRT) has been reported to induce hypertrophy of the contralateral, untreated liver lobe. The aim of this study was to review the current literature reporting on contralateral liver hypertrophy induced by unilobar SIRT...
October 16, 2015: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/26128567/mo-a-brd-02-physics-perspective
#17
S Kappadath
UNLABELLED: Yttrium-90 (Y90) microsphere therapy, a form of radiation therapy, is an increasingly popular option for care of patients with liver metastases or unresectable hepatocellular carcinoma. The therapy directly delivers Y90 microspheres via the hepatic artery to disease sites. Following delivery, a vast majority of microspheres preferentially lodge in the capillary vessels due to their embolic size and targeted trans-arterial delivery - depositing up to 90% of its energy in the first 5 mm of tissue...
June 2015: Medical Physics
https://www.readbyqxmd.com/read/26128566/mo-a-brd-00-current-trends-in-y90-microsphere-therapy-delivery-and-dosimetry
#18
(no author information available yet)
UNLABELLED: Yttrium-90 (Y90) microsphere therapy, a form of radiation therapy, is an increasingly popular option for care of patients with liver metastases or unresectable hepatocellular carcinoma. The therapy directly delivers Y90 microspheres via the hepatic artery to disease sites. Following delivery, a vast majority of microspheres preferentially lodge in the capillary vessels due to their embolic size and targeted trans-arterial delivery - depositing up to 90% of its energy in the first 5 mm of tissue...
June 2015: Medical Physics
https://www.readbyqxmd.com/read/26128565/mo-a-brd-01-clinical-perspective
#19
A Mahvash
UNLABELLED: Yttrium-90 (Y90) microsphere therapy, a form of radiation therapy, is an increasingly popular option for care of patients with liver metastases or unresectable hepatocellular carcinoma. The therapy directly delivers Y90 microspheres via the hepatic artery to disease sites. Following delivery, a vast majority of microspheres preferentially lodge in the capillary vessels due to their embolic size and targeted trans-arterial delivery - depositing up to 90% of its energy in the first 5 mm of tissue...
June 2015: Medical Physics
https://www.readbyqxmd.com/read/26127217/su-d-201-02-prediction-of-delivered-dose-based-on-a-joint-histogram-of-ct-and-fdg-pet-images
#20
M Park, Y Choi, A Cho, S Hwang, J Cha, N Lee, M Yun
PURPOSE: To investigate whether pre-treatment images can be used in predicting microsphere distribution in tumors. When intra-arterial radioembolization using Y90 microspheres was performed, the microspheres were often delivered non-uniformly within the tumor, which could lead to an inefficient therapy. Therefore, it is important to estimate the distribution of microspheres. METHODS: Early arterial phase CT and FDG PET images were acquired for patients with primary liver cancer prior to radioembolization (RE) using Y90 microspheres...
June 2015: Medical Physics
keyword
keyword
63897
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"